KB-1222

Nivolumab

Background

PD-1 (programmed death Receptor 1), also known as CD279 (differentiated cluster 279), is an important immunosuppressive molecule. Regulates the immune system and promotes self-tolerance by down-regulating the immune system's response to human cells, as well as by suppressing T cell inflammatory activity. Nivolumab can specifically attach to the PD-1 receptor of T cells and prevent T cell inactivation, thereby blocking the immune escape of cancer cells and improving the immune stem's ability to kill cancer cells.

Specifications

Catalog Number:
KB-1222
Cell Line Name:
Nivolumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
PD1
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Kortnye Maureen Smith , Jayesh Desai . Nivolumab for the treatment of colorectal cancer.Expert Rev Anticancer Ther. 2018 Jul;18(7):611-618. 2.Pengpeng Liu , Xiangyu Pan , Chong Chen , Ting Niu , Xiao Shuai , Jian Wang , Xuelan Chen , Jiazhuo Liu , Yong Guo , Liping Xie , Yu Wu , Yu Liu , Ting Liu .Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults.Blood. 2020 Mar 12;135(11):826-833.
Please enable JavaScript in your browser to complete this form.